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Background: Identification of men harbouring insignificant prostate cancer (PC) is important in selecting patients for active
surveillance. Tools have been developed in PSA-screened populations to identify such men based on clinical and biopsy
parameters.
Methods: Prospectively collected case series of 848 patients was treated with radical prostatectomy between July 2007 and
October 2011 at an English tertiary care centre. Tumour volume was assessed by pathological examination. For each tool, receiver
operator characteristics were calculated for predicting insignificant disease by three different criteria and the area under each
curve compared. Comparison of accuracy in screened and unscreened populations was performed.
Results: Of 848 patients, 415 had Gleason 3þ 3 disease on biopsy. Of these, 32.0% had extra-prostatic extension and 50.2% were
upgraded. One had positive lymph nodes. Two hundred and six (24% of cohort) were D’Amico low risk. Of these, 143 had more
than two biopsy cores involved. None of the tools evaluated has adequate discriminative power in predicting insignificant tumour
burden. Accuracy is low in PSA-screened and -unscreened populations.
Conclusions: In our unscreened population, tools designed to identify insignificant PC are inaccurate. Detection of a wider size
range of prostate tumours in the unscreened may contribute to relative inaccuracy.
Clinically insignificant prostate cancer (PC) can be defined as a
cancer, which will not affect the patient during the natural course of
his lifetime. The indolent course of localised low-grade PC means
that active surveillance (AS) is considered a good treatment option
(Albertsen et al, 2005). Recent data regarding the apparent
overtreatment of screening detected PC has provoked much debate
regarding the way low-risk PC is treated. Generalisation of
conclusions from studies where PSA screening is common to
populations where PSA testing is relatively uncommon is misleading.
Attempts have been made to define clinically insignificant PC,
based on pathological examination of radical prostatectomy speci-
mens and analysis of recurrence rates of these tumours. Several
definitions have been formulated. Work by Stamey et al (1993)
identified organ-confined tumours of o0.5 cm3 Gleason 3þ 3 with
no grade 4 or 5 as insignificant. Subsequently, Wolters et al (2011)
analysed the data from the European Randomised Study of
screening for PC (ERSPC) (van den Bergh et al, 2009) to redefine
insignificant PC as organ-confined Gleason 3þ 3 tumours, with no
grade 4 or 5, the largest tumour having a volume p1.3 cm3 and a
total tumour volume ofp2.5 cm3. Evidence of tumour volume as an
independent predictor of outcome in PC is conflicting, and therefore
we considered definitions of insignificant PC that include and
exclude tumour volume.
A number of tools have been developed to identify men who are
harbouring insignificant PC. The tools are based on parameters
defined by clinical examination, serum PSA, transrectal ultrasound
findings and biopsy results. These tools have been generated in
populations where PSA screening is common from USA (Soloway
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et al, 2010; Adamy et al, 2011; Tosoian et al, 2011; Whitson et al,
2011) and from the ERSPC study (van den Bergh et al, 2009). In
the UK, the uptake of PSA testing is B6% (Melia et al, 2004;
Parker et al, 2006). We sought to evaluate the accuracy of these
tools in identifying insignificant PC (by three different definitions)
in a cohort of patients undergoing radical prostatectomy.
Objectives. To evaluate the accuracy of tools designed to identify
insignificant PC in a cohort of patients undergoing radical
prostatectomy in an unscreened population.
Second, we sought to evaluate the effect of PSA screening on the
accuracy of these tools.
MATERIALS AND METHODS
Data were collected prospectively for 847 patients undergoing
robotic radical prostatectomy between July 2007 and October 2011
at Addenbrookes Hospital, Cambridge, UK. The PSA level was
measured and clinical stage assigned by the attending urologist
according to the 2002 TNM staging system. All patients had their
biopsy and radical prostatectomy specimens evaluated at our
institution by genitourinary pathologists according to protocols
from the Royal College of Pathologists (2009).
Data were reviewed retrospectively and 445 patients who had
Gleason 3þ 3 on biopsy were identified. Of these, in 415 patients, a
specialist uropathologist had estimated tumour volume in the
radical prostatectomy specimen at the time of initial histopatho-
logical evaluation using a visual inspection method of assessment
of marked areas of tumour on whole-mount haematoxylin and
eosin stained sections from the entirely embedded prostates (van
der Kwast et al, 2011).
The histology sections were divided in halves or quadrants to
fit cassettes for paraffin embedding. Pathological tumour stage
and Gleason grade were assessed. Tumour areas were marked on
each slide and measured by visual estimation, giving a percentage
of the total volume of prostate occupied by tumour (van der
Kwast et al, 2011). Subsequently, the volumes of tumour were
calculated by multiplying the percentage occupied area by the
gland volume (itself calculated by measurement of diameters of
resected prostate specimen HW L p/6 (MacMahon et al,
2009)). For 537 patients, the weight of the prostate specimen with
seminal vesicles removed was available. Where diagnostic TRUS
was performed at the referring centre, we were not able to
calculate PSA density using TRUS volume. TRUS-estimated
volume was available for 256 patients. In these patients, we used
the calculated volume of the resected prostate to calculate
approximate PSA density. Strong agreement was seen between
prostate weight and calculated prostate volume, and between
TRUS-estimated volume and calculated prostate volume (data not
shown).
Postoperative assessments included physical examination and
PSA at 6 weeks, 3, 9 and 12 months and every 6 months thereafter.
Biochemical recurrence was defined as PSA 40.2 ngml 1.
Five criteria designed to identify insignificant disease were
identified (Table 1) and performance compared with D’Amico
low-risk criteria (PSAp10, Gleason 3þ 3, cT1-2a) (D’Amico et al,
1998). In addition, the discriminative power of the selection criteria
used for a UK AS cohort (Selvadurai et al, 2013) and the effect of
the number of biopsy cores (Ochiai et al, 2005) containing cancer
were evaluated.
Three different criteria were used to define insignificant PC:
1. Classical definition¼ organ-confined tumours of o0.5 cm3
Gleason 3þ 3 with no Gleason 4 or 5 (Stamey et al, 1993).
2. ERSPC definition¼ organ-confined Gleason 3þ 3 tumours,
with no Gleason grade 4 or 5, index tumour volume
p1.3 cm3 and a total tumour volume of p2.5 cm3 (Wolters
et al, 2011).
3. Inclusive definition¼ organ-confined Gleason 3þ 3 tumours,
with no Gleason grade 4 or 5.
Receiver operator characteristics (ROC) were plotted for each of
the tools in predicting insignificant disease by each of the three
definitions and the area under the ROC curve (AUC) calculated.
Comparisons with the D’Amico tool were made using the DeLong
method (DeLong et al, 1988).
The D’Amico risk stratification tool was not designed to facilitate
selection of patients for AS but as a means to predict outcome
following radical therapy (D’Amico et al, 1998). It is included here as
a benchmark for comparison with tools designed for this purpose.
Its use as a predictor of outcome in other treatment modalities has
been taken up in the UK (Graham et al, 2008).
Sensitivity, specificity, positive predictive value and negative
predictive value were calculated to assess the performance of each
tool under each of the three criteria. We also considered two
additional tools: ‘any criteria’, which saw the patient recorded as
eligible for AS if any one of the tools indicated he was low risk, and
‘all criteria’, which saw the patient recorded as eligible for AS only
if all of the tools indicated he was low risk.
The tools for identifying patients suitable for AS were examined
using univariable Cox regression. Unless otherwise stated, P-values
were calculated based on two-sided hypothesis tests and are
corrected for multiple comparisons using a Bonferroni correction.
Table 1. Components of tools by which to identify patients bearing insignificant PC
Prostate biopsy result
Reference PSA (ngml1)
Number of positive
cores Core involvement Clinical stage
Tosoian et al, 2011 Density p0.15 p2 p50 T1
Adamy et al, 2011 p10 p3 p50 T1-2a
van den Bergh et al, 2009 p10 and density o0.2ml1 p2 — T1c-2
Whitson et al, 2011 p10 p33% (of at least 6) p50 T1c-2
Soloway et al, 2010 p15 p2 p50 T1c-2
D’Amico et al, 1998 p10 — — T1
Selvadurai et al, 2013 p15 — p50 T1-2
Abbreviation: PC¼prostate cancer.
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A cutoff of 0.05 was used to determine statistical significance.
Statistical analysis was performed using Stata 11 (StataCorp LP
2009, College Station, TX, USA).
RESULTS
Of the 847 patients treated with robotic radical prostatectomy, 415
had Gleason 3þ 3 disease on their diagnostic biopsy and tumour
volume estimated after prostatectomy. Of these, 206 patients had
D’Amico low risk disease PC (D’Amico et al, 1998). It has been
shown that the number of cores on diagnostic biopsy was affected
by cancer correlates with tumour volume (Ochiai et al, 2005). Only
63 patients undergoing surgery had two or fewer cores containing
cancer on diagnostic biopsy (all biopsies had 10–12 cores taken)
and these men had expressed a strong desire not to pursue AS after
careful counselling about the relative merits of AS.
Two hundred and nine out of 415 (50.3%) had Gleason 4 or 5 PC,
131 out of 415 (31.6%) demonstrated extra-capsular extension and 1 out
of 415 (0.2%) had positive nodes at surgery, a rate of misclassification in
keeping with other non-USA series (Kim et al, 2013).
The selection criteria evaluated vary in their stringency. The more
stringent criteria render fewer patients eligible for AS, although the
number of patients offered AS for significant disease is decreased.
Table 2 demonstrates this principle with Toisiain criteria selecting
only 3 of 44 (7%) patients with pT3 tumours for AS and the
Whitson criteria 39 of 169 (23%) of eligible patients who had pT3
disease. The less-stringent criteria tended to select patients bearing
larger tumours. The receiver operator characteristics are shown in
Tables 3 and 4. No significant difference in discriminative power is
demonstrated for any tool over D’Amico low-risk criteria other than
a significant inferiority for the Selvadurai criteria in identifying
insignificant disease by the ERSPC definition.
From a pragmatic point of view, the urologist needs to know
how many people identified as having insignificant PC by each
criteria will turn out to be harbouring significant disease. Table 5
demonstrates the stringency and discriminative power of each tool.
Iremashvili et al (2012) compared accuracy of the five tools in
predicting insignificant PC in a cohort of North American patients.
Table 6 demonstrates the relative accuracy of these tools in our and
the Iremashvili cohorts. The AUC did not exceed 0.7 for any of the
tools evaluated in either the UK or USA cohorts. Consensus
suggests that a test with an AUC of o0.7 is of limited
discriminative power (DeLong et al, 1988). In the USA data, the
AUCs approached 0.7 for some of the tools predicting insignificant
PC by each of the definitions. In the UK cohort none of the AUCs
exceeded 0.6.
One limitation of this study is that this cohort of surgical
patients may not necessarily be representative of all patients with
Gleason 3þ 3 PC on biopsy. The small number of classically
defined insignificant PC (n¼ 18) seen limits our ability to analyse
this subgroup.
DISCUSSION
The recent publication of the PIVOT trial data has provoked much
debate (Wilt et al, 2012). PSA screening is commonplace in the USA
(for example, in the PLCO randomised study of PSA screening, at
enrolment 44% of the men in the ‘unscreened’ arm and this
increased to 77% after 5 years on the study (Andriole et al, 2009)). In
the UK, PSA testing is performed on an ad hoc basis and it is
estimated that only 6% of men will have had a PSA test (Melia et al,
2004; Parker et al, 2006). In the USA, the PIVOT study failed to
demonstrate a difference in overall survival for men with low-risk
PC treated with radical surgery or observation. Conversely, the
SPCG-4 study, from an unscreened Scandinavian population,
demonstrated a significant survival benefit to radical prostatectomy
(Bill-Axelson et al, 2011). Analyses of PIVOT trial data compared
with SPCG-4 data suggest that PSA screening results in over
diagnosis and lead-time effect (Xia et al, 2013). It has been estimated
using the ERSPC data that this lead time is 11 years (Draisma et al,
2003). Assuming that tumours grow with time, it is logical that
screen-detected PCs will be of lower volume than their non-screen-
detected counterparts as demonstrated by our data. Examination of
ERSPC data reveals a median tumour size of 0.47 cm3 (Draisma
et al, 2003). Only 4% of our cohort had tumour sizep0.47 cm3 with
a median tumour volume of 3.47 cm3 (see Figure 1).
The accuracy of a diagnostic test can be evaluated by calculating
the AUC. The AUC for a random act, like a coin toss, is 0.5. The
accepted rule of thumb is that an AUC of o0.7 indicates poor
discriminative power; between 0.7 and 0.8 indicates acceptable
Table 2. Pathological tumour characteristics in patients identified as bearing insignificant PC by the selection tools described
Tosoian Adamy
Van den
Bergh Whitson Soloway Selvadurai D’Amico
Any
criteria All criteria
Patients, n (%) 44 (10.7) 146 (35.6) 63 (15.4) 169 (41.2) 106 (25.9) 306 (74.6) 206 (49.6) 339 (82.7) 43 (10.5)
Pathological Gleason score, n (%)
2–6 28 (6.8) 85 (20.7) 41 (10.0) 93 (22.7) 58 (14.1) 151 (36.8) 109 (28.6) 169 (41.2) 27 (6.6)
7 14 (3.4) 57 (13.9) 20 (4.9) 71 (17.3) 44 (10.7) 145 (35.4) 91 (21.8) 160 (39.0) 14 (3.4)
8–10 2 (0.5) 4 (1.0) 2 (0.5) 5 (1.2) 4 (1.0) 10 (2.4) 6 (1.4) 10 (2.4) 2 (0.5)
Pathological stage, n (%)
XpT3 3 (0.7) 28 (6.8) 6 (1.5) 39 (9.5) 14 (3.5) 90 (22.0) 71 (17.4) 106 (25.9) 3 (0.7)
XpT3b 0 (0.0) 2 (0.5) 1 (0.2) 2 (0.5) 2 (0.5) 7 (1.7) 3 (0.7) 7 (1.7) 0 (0.0)
Positive margins, n (%) 3 (0.7) 25(6.1) 7 (1.7) 33 (8.1) 16 (3.9) 58 (14.2) 46 (11.3) 65 (15.9) 3 (0.7)
Tumour volume, cc, median (IQR) 1.7 (1.0–3.1) 2.7 (1.3–4.7) 2.5 (1.1–3.9) 2.9 (1.5–5.3) 2.4 (1.1–4.6) 3.4 (1.8–6.3) 3.0 (1.7–5.4) 3.6 (1.9–6.5) 1.6 (1.0–3.2)
Largest tumour volume (where multiple
tumours), cc, median (IQR)
1.3 (0.9–2.3) 2.2 (1.0–3.5) 1.8 (0.8–3.2) 2.5 (1.1–3.8) 1.9 (1.0–3.7) 2.8 (1.5–4.4) 2.7 (1.5–4.4) 3.0 (1.6–5.2) 1.4 (0.7–2.6)
Insignificant cancers, classical definition, n (%) 3 (0.7) 9 (2.2) 3 (0.7) 9 (2.2) 8 (2.0) 12 (2.9) 9 (2.2) 12 (2.9) 3 (0.7)
Insignificant cancers, ERSPC definition, n (%) 17 (4.2) 45 (11.0) 22 (5.4) 47 (11.5) 36 (8.8) 66 (16.1) 51 (12.3) 73 (17.8) 16 (3.9)
Organ-confined low-grade cancer, n (%) 28 (6.8) 81 (19.8) 39 (9.5) 88 (21.5) 57 (13.9) 134 (32.7) 97 (23.4) 147 (35.9) 27 (6.6)
Abbreviations: ERSPC¼European Randomised Study of screening for prostate cancer; IQR¼ interquartile range; PC¼prostate cancer.
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discrimination; and 40.8 indicates excellent discriminative ability
(DeLong et al, 1988).
In 2012, Iremashvili et al (2012) published data examining the
accuracy of protocols for selecting patients for AS in a USA cohort.
The AUCs ranged from 0.61 to 0.68 for classically defined
insignificant PC, 0.59 to 0.64 for updated definition and 0.55 to
0.62 for organ-confined low-grade disease. This compares with
0.51 to 0.60, 0.54 to 0.57 and 0.54 to 0.59, respectively, in our
cohort. None of the selection tools evaluated had an AUC of40.7
in either cohort. There was a trend towards the AUCs being lower
in the UK cohort compared with corresponding USA data. We
hypothesise that tools based on number or length of biopsy cores
are rendered inaccurate due to greater variability in the size of PCs
detected.
Two or fewer cancer-containing cores has been shown to
correlate with tumour volume in US series (Ochiai et al, 2005).
Selecting only patients with two or fewer cores on biopsy or very
low-risk disease (D’Amico low risk with two or fewer cores
effected) did not improve accuracy in detecting insignificant
disease over D’Amico risk stratification alone (Tables 3 and 4).
The recent recommendations of the US preventative task force
on PC screening (Moyer, 2012) and the AUA (Carter et al, 2013)
may result in changes in the uptake of PSA screening worldwide
with potential effects on the accuracy of these tools.
Table 3. Comparison of the diagnostic accuracy of selection tools in identifying patients bearing insignificant PC defined in three different ways
Insignificant cancer, classical definition Insignificant cancer, ERSPC definition Organ-confined low-grade cancer
Approach Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Tosoian 0.17 0.9 0.07 0.96 0.18 0.91 0.39 0.78 0.16 0.93 0.64 0.59
Adamy 0.5 0.65 0.06 0.97 0.46 0.68 0.31 0.8 0.45 0.72 0.56 0.63
Van den Bergh 0.17 0.85 0.05 0.96 0.23 0.87 0.35 0.78 0.22 0.9 0.62 0.6
Whitson 0.5 0.59 0.05 0.96 0.49 0.61 0.28 0.79 0.49 0.65 0.52 0.62
Soloway 0.44 0.75 0.08 0.97 0.37 0.78 0.34 0.8 0.32 0.79 0.54 0.6
Selvadurai 0.67 0.25 0.04 0.94 0.68 0.23 0.22 0.7 0.75 0.26 0.44 0.57
D’Amico 0.61 0.36 0.04 0.95 0.67 0.37 0.25 0.79 0.69 0.4 0.47 0.62
Any criteria 0.67 0.17 0.04 0.92 0.75 0.15 0.22 0.66 0.82 0.17 0.43 0.55
All criteria 0.17 0.9 0.07 0.96 0.17 0.91 0.37 0.78 0.15 0.93 0.63 0.59
Cancer cores p2 0.5 0.63 0.06 0.97 0.46 0.65 0.29 0.8 0.44 0.67 0.51 0.61
Very low riska 0.44 0.72 0.07 0.97 0.42 0.75 0.35 0.81 0.38 0.78 0.58 0.62
Abbreviations: NPV¼ negative predictive value; PC¼prostate cancer; PPV¼positive predictive value.
aVery low risk¼D’Amico low risk with two or fewer biopsy cores containing cancer.
Table 4. Comparison of the areas under the receiver operator characteristic curves of the selection tools
Insignificant cancer, classical
definition
Insignificant cancer, ERSPC definition Organ-confined low-grade cancer
Approach AUC
95%
confidence
interval
Comparison
with D’Amico
approacha,
adjusted
P-value AUC
95%
confidence
interval
Comparison
with D’Amico
approacha,
adjusted
P-value AUC
95%
confidence
interval
Comparison
with D’Amico
approacha,
adjusted
P-value
Tosoian 0.53 0.44–0.62 1 0.54 0.50–0.59 1 0.54 0.51–0.58 1
Adamy 0.58 0.45–0.70 0.26 0.57 0.51–0.63 0.462 0.59 0.54–0.63 0.652
Van den Bergh 0.51 0.42–0.60 1 0.55 0.50–0.59 1 0.56 0.52–0.59 1
Whitson 0.55 0.43–0.67 1 0.55 0.49–0.60 1 0.57 0.52–0.62 1
Soloway 0.6 0.48–0.72 0.76 0.57 0.52–0.63 0.882 0.55 0.51–0.60 1
Selvadurai 0.46 0.34–0.57 1 0.46 0.41–0.51 0.024 0.5 0.46–0.55 0.418
D’Amico 0.49 0.37–0.61 — 0.52 0.47–0.58 — 0.55 0.50–0.59 —
Any criteria 0.42 0.30–0.53 0.171 0.45 0.40–0.50 0.001 0.5 0.46–0.53 0.084
All criteria 0.53 0.44–0.62 1 0.54 0.50–0.58 1 0.54 0.51–0.57 1
Cancer cores p2 0.56 0.44–0.69 1 0.56 0.50–0.61 1 0.56 0.51–0.60 1
Very low risk 0.58 0.46–0.70 0.418 0.58 0.53–0.64 0.105 0.58 0.54–0.63 1
Abbreviations: AUC¼ area under the receiver operator characteristic curve; ERSPC¼European Randomised Study of screening for prostate cancer. P-values o0.05 are shown in bold.
aNull hypothesis: AUC i¼AUC D’Amico, two-sided alternative hypothesis: AUC iaAUC D’Amico. Comparison made using the DeLong method (DeLong et al, 1988).
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Data from maturing AS cohorts suggest the short-term safety of
an inclusive approach (Klotz, 2013; Selvadurai et al, 2013).
However, 30% of patients on AS undergo radical treatment within
5 years. Upgrading and upstaging at surgery were common events
in our cohort. It is possible that with increasing follow-up the
number of patients failing conservative therapy will increase and
while they are on AS they continue to age, rendering them less
suitable for surgical treatment.
Considered together these data suggest a substantial under-
diagnosis and would justify exhaustive investigation early in the
course of an AS programme. The approach in our unit, in an
attempt to minimise underdiagnosis, following a diagnosis of low-
risk PC is to perform a multiparametric MRI with repeat TRUS at
3 months. The MRI is performed after a suitable period following
the diagnostic biopsy to exclude false positives due to biopsy
artefact. If the MRI demonstrates a lesion likely to have been
missed on TRUS-guided biopsy, targeted transperineal biopsy is
performed. Inter-operator variability in interpreting MRI means
that in some centres the use of systematic transperineal template
biopsy is rational (Ayres et al, 2012). Where expertise in MRI is
available, targeted biopsy may help rule out aggressive disease for
those men who are unwilling to accept the inaccuracy associated
with staging and grading of PC by TRUS biopsy, PSA and clinical
examination.
This study highlights the uncertainty associated with selecting
men for AS; although long-term data from AS series are awaited, it
is clear that there is an urgent need for a biomarker by which to
differentiate indolent from aggressive PC. Heterogeneity within PC
Table 5. Number of patients identified correctly and incorrectly as bearing insignificant PC and therefore being eligible for active surveillance
Tosoian Adamy
Van den
Bergh Whitson Soloway Selvadurai D’Amico
Entire
cohort
Insignificant cancer, classical definition
Correctly eligible for AS 3 9 3 9 8 12 9 20
Incorrectly eligible for AS 41 137 60 160 98 294 197 396
Total eligible for AS 44 146 63 169 106 306 206 415
Percent of eligible patients correctly identified as
insignificant PC
7 6 5 5 8 4 4 5
Insignificant cancer, ERSPC definition
Correctly eligible for AS 17 45 22 47 36 66 51 99
Incorrectly eligible for AS 27 101 41 122 70 240 155 316
Total eligible for AS 44 146 63 169 106 306 206 415
Percent of eligible patients correctly identified as
insignificant PC
39 31 35 28 34 22 25 24
Organ-confined low-grade cancer
Correctly eligible for AS 28 81 39 88 57 134 97 181
Incorrectly eligible for AS 16 65 24 81 49 172 109 234
Total eligible for AS 44 146 63 169 106 306 206 415
Percent of eligible patients correctly identified as
insignificant PC
64 55 62 52 54 44 47 44
Abbreviations: AS¼ active surveillance; AUC¼ area under the receiver operator characteristic curve; ERSPC¼European Randomised Study of screening for prostate cancer; PC¼prostate
cancer.
Table 6. Comparison of accuracy of tools in unscreened UK and screened USA data sets
Insignificant cancer, classical definition Insignificant cancer, ERSPC definition Organ-confined low-grade cancer
This study
Iremashvili et al,
2012 This study
Iremashvili et al,
2012 This study
Iremashvili et al,
2012
Approach AUC
95%
confidence
interval AUC
95%
confidence
interval AUC
95%
confidence
interval AUC
95%
confidence
interval AUC
95%
confidence
interval AUC
95%
confidence
interval
Tosoian 0.53 0.44–0.62 0.63 0.59–0.68 0.54 0.50–0.59 0.6 0.56–0.63 0.54 0.51–0.58 0.59 0.54–0.63
Adamy 0.58 0.45–0.70 0.63 0.58–0.67 0.57 0.51–0.63 0.62 0.57–0.67 0.59 0.54–0.63 0.59 0.54–0.64
Van den Bergh 0.51 0.42–0.60 0.68 0.63–0.72 0.55 0.50–0.59 0.64 0.60–0.69 0.56 0.52–0.59 0.62 0.57–0.67
Whitson 0.55 0.43–0.67 0.61 0.57–0.65 0.55 0.49–0.60 0.59 0.55–0.64 0.57 0.52–0.62 0.56 0.51–0.61
Soloway 0.6 0.48–0.72 0.68 0.64–0.73 0.57 0.52–0.63 0.63 0.58–0.67 0.55 0.51–0.60 0.6 0.55–0.65
Any criteria 0.42 0.30–0.53 0.61 0.57-0.65 0.45 0.40–0.50 0.58 0.54–0.63 0.5 0.46–0.53 0.55 0.50–0.60
All criteria 0.53 0.44–0.62 0.63 0.59–0.68 0.54 0.50–0.58 0.6 0.56–0.64 0.54 0.51–0.57 0.58 0.54–0.62
Abbreviations: AUC¼ area under the receiver operator characteristic curve; ERSPC¼European Randomised Study of screening for prostate cancer.
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tumours means that the sampling error inherent to random or
systemic needle biopsy of the prostate will continue to result in
misdiagnosis. This error is unlikely to be negated using genomic or
expressome analysis of tumour samples, where sampling error is
still a problem. Further work should focus on imaging tests where
areas suspicious for aggressive cancer can be identified and
targeted for biopsy. Multiparametric magnetic resonance imaging
is currently the best way to identify significant PC. In the future,
positron emission tomography using tracers taken up specifically
by aggressive tumour foci may prove useful.
CONCLUSIONS
Tools to identify insignificant PC are inaccurate in an unscreened
population. This illustrates the great caution needed when using a
tool developed and validated in one population in another
population, particularly when PSA screening is a confounding
factor. In counselling patients for AS, the surgeon should be
explicit regarding uncertainty in predicting stage/grade despite
apparent short-term safety. There is an urgent need for develop-
ment of a means by which to exclude aggressive PC in patients
wishing to undergo conservative treatment.
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Figure 1. Bar chart of distribution of tumour volumes in screened and
unscreened populations (we acknowledge technical differences in the
method of calculation of tumour volume).
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